Relative Importance of History of Heart Failure Hospitalization and N-Terminal Pro-B-Type Natriuretic Peptide Level as Predictors of Outcomes in Patients With Heart Failure and Preserved Ejection Fraction

JACC: Heart Failure

Volumn 3, Issue 6, 2015, Pages 478-486

  Kristensen, Søren L ^a,b   Jhund, Pardeep S ^a   Køber, Lars ^c   McKelvie, Robert S ^d   Zile, Michael R ^e   Anand, Inder S ^f   Komajda, Michel ^g   Cleland, John G F ^h   Carson, Peter E ⁱ   McMurray, John J V ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b GENTOFTE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

^d MCMASTER UNIVERSITY   (Canada)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f UNIVERSITY OF MINNESOTA   (United States)

^g SORBONNE UNIVERSITÉ   (France)

^h HAREFIELD HOSPITAL   (United Kingdom)

ⁱ GEORGETOWN UNIVERSITY   (United States)

Author keywords

Heart failure; Heart failure with preserved ejection fraction; NT proBNP outcomes; Prognostic markers

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIGOXIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; IRBESARTAN; LOOP DIURETIC AGENT; MINERALOCORTICOID ANTAGONIST; PLACEBO; BRAIN NATRIURETIC PEPTIDE; PEPTIDE FRAGMENT; PRO-BRAIN NATRIURETIC PEPTIDE (1-76);

ADULT; AGED; ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; CARDIOVASCULAR RISK; FEMALE; HEART DEATH; HEART FAILURE; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL (TOPIC); BLOOD; HEART STROKE VOLUME; MORTALITY; PATHOPHYSIOLOGY; PHYSIOLOGY; PREDICTIVE VALUE; PROPORTIONAL HAZARDS MODEL; RISK FACTOR; STATISTICS AND NUMERICAL DATA;

AGED; FEMALE; HEART FAILURE; HOSPITALIZATION; HUMANS; MALE; NATRIURETIC PEPTIDE, BRAIN; PEPTIDE FRAGMENTS; PREDICTIVE VALUE OF TESTS; PROPORTIONAL HAZARDS MODELS; RISK FACTORS; STROKE VOLUME;

EID: 84930849166     PISSN: 22131779     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jchf.2015.01.014     Document Type: Article

References (10)

1. Krumholz H.M., Parent E.M., Tu N., et al. Readmission after hospitalization for congestive heart failure among Medicare beneficiaries. Arch Interm Med 1997, 157:99-104.
2. Abrahamsson P., Swedberg K., Borer J.S., et al. Risk following hospitalization in stable chronic systolic heart failure. Eur J Heart Fail 2013, 15:885-891.
3. Solomon S.D., Dobson J., Pocock S., et al. Influence of nonfatal hospitalization for heart failure on subsequent mortality in patients with chronic heart failure. Circulation 2007, 116:1482-1487.
4. Pitt B., Pfeffer M.A., Assmann S.F., et al. Spironolactone for heart failure with preserved ejection fraction. NEngl J Med 2014, 370:1383-1392.
5. McMurray J.J., O'Connor C. Lessons from the TOPCAT trial. NEngl J Med 2014, 370:1453-1454.
6. Massie B.M., Carson P.E., McMurray J.J., et al. Irbesartan in patients with heart failure and preserved ejection fraction. NEngl J Med 2008, 359:2456-2467.
7. Carson P., Massie B.M., McKelvie R., et al. The Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) trial: rationale and design. JCard Fail 2005, 11:576-585.
8. Komajda M., Carson P.E., Hetzel S., et al. Factors associated with outcome in heart failure with preserved ejection fraction: findings from the Irbesartan in Heart Failure with Preserved Ejection Fraction Study (I-PRESERVE). Circ Heart Fail 2011, 4:27-35.
9. McKelvie R.S., Komajda M., McMurray J., et al. Baseline plasma NT-proBNP and clinical characteristics: results from the irbesartan in heart failure with preserved ejection fraction trial. JCard Fail 2010, 16:128-134.
10. Yusuf S., Pfeffer M.A., Swedberg K., et al. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet 2003, 362:777-781.